Country Selector
TRUST IN EXCELLENCE
Vifor Pharma Group, formerly Galenica Group, is a global pharmaceutical company that researches, develops, produces and markets its own pharmaceutical products and is the partner of choice for innovative, patient-focused solutions.
INVESTORS
The Galenica Group changed its name to Vifor Pharma Group at the Annual General Meeting in May 2017, with the vision of becoming a Global Leader in Iron Deficiency, Nephrology and Cardio-Renal Therapies.
RELYPSA
Relypsa, Inc., a Vifor Pharma Group company, is a biopharmaceutical company focused on the discovery, development and commercialisation of polymeric medicines for patients with conditions that are often overlooked and undertreated.
Vifor Pharma is a leader in iron deficiency therapy, with a history dating back to 1872 when pharmacist Caspar Friedrich Hausmann opened a pharmacy in St. Gallen, Switzerland, and developed infusion preparations and pharmaceutical specialities.
We have a broad and diversified offering in nephrology and cardio-renal therapies.
READ MORE: VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA
The Vifor Pharma Infectious Diseases / OTX franchise focuses on a range of over-the-counter and OTX (prescribed non-prescription) products.
PRESS RELEASES
VFMCRP AND CARA THERAPEUTICS TO DEVELOP AND COMMERCIALISE CR845 INJECTION FOR CHRONIC KIDNEY DISEASE-ASSOCIATED PRURITUS
23.05.2018
90TH VIFOR PHARMA GROUP ANNUAL SHAREHOLDER MEETING
15.05.2018
US FDA APPROVES USE OF VELTASSA® WITH OR WITHOUT FOOD
08.05.2018
VIFOR PHARMA TO PROPOSE JACQUES THEURILLAT AS BOARD MEMBER
29.03.2018
VIFOR PHARMA CONCLUDES LICENSING AGREEMENT WITH ZERIA TO MARKET VELTASSA® IN JAPAN
27.03.2018
VIFOR PHARMA GROUP REPORTS STRONG 2017 RESULTS, EXCEEDING RAISED GUIDANCE
15.03.2018
VIFOR PHARMA FERROPORTIN INHIBITOR ENTERS PHASE-I CLINICAL TRIAL
08.02.2018
AVACOPAN CONDITIONAL MARKETING AUTHORIZATION APPLICATION ACCEPTED FOR REGULATORY REVIEW BY EUROPEAN MEDICINES AGENCY
04.01.2018
VELTASSA® APPROVED FOR MARKETING IN SWITZERLAND FOR THE TREATMENT OF HYPERKALAEMIA
THIRD GLOBAL IRON DEFICIENCY DAY TO RAISE AWARENESS OF THE SYMPTOMS OF IRON DEFICIENCY
23.11.2017
VIFOR PHARMA EXPANDS EXCLUSIVE LICENSE AGREEMENT FOR THE COMMERCIALISATION OF MIRCERA® IN THE US
27.09.2017
VIFOR PHARMA REPORTS STRONG H1 2017 RESULTS AND RAISES GUIDANCE
08.08.2017
EUROPEAN COMMISSION APPROVES MARKETING AUTHORISATION FOR VELTASSA®
21.07.2017
NEW EXPERT REVIEW IN THE AMERICAN JOURNAL OF HEMATOLOGY SEEKS TO CHANGE THE WAY WE TEST, TREAT AND TALK ABOUT IRON DEFICIENCY IN CHRONIC INFLAMMATORY CONDITIONS
18.07.2017
VIFOR PHARMA ANNOUNCES THREE OUTCOMES TRIALS IN HEART FAILURE AND IRON DEFICIENCY
12.07.2017
KISSEI TO MARKET AVACOPAN IN JAPAN FOR VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA
09.06.2017
CHMP RECOMMENDS VELTASSA® FOR THE TREATMENT OF HYPERKALAEMIA IN THE EU
19.05.2017
89th Annual General Meeting of Galenica Ltd.
11.05.2017
Vifor Pharma and ChemoCentryx Announce Expansion of Kidney Health Alliance to Include CCX140 to Treat Renal Diseases
23.12.2016
EFFECT-HF demonstrates a significantly beneficial effect of Ferinject® on exercise capacity among patients with CHF and iron deficiency - confirms findings of previous studies
07.12.2016
FDA Approves Supplemental New Drug Application for Veltassa® Removing Boxed Warning Regarding Drug-Drug Interactions
28.11.2016
Vifor Pharma leads initiatives to raise awareness of Iron Deficiency - 2nd Global Iron Deficiency Day on November 26, 2016
24.11.2016
Appointments at the Galenica Group: New management at Vifor Pharma and new Galenica Group CFO designated
06.10.2016
Galenica completes acquisition of Relypsa, strengthening Vifor Pharma's position in cardio-renal therapies
02.09.2016
Galenica announces Expiration of Cash Tender Offer for Shares of Common Stock of Relypsa
01.09.2016
Galenica commences Tender Offer for Relypsa
04.08.2016
Galenica to acquire Relypsa to strengthen its Business unit Vifor Pharma
21.07.2016
Vifor Pharma expands ESA product portfolio with rights to commercialise Pfizer's proposed epoetin alfa biosimilar, Retacrit(TM), in the US dialysis market
24.05.2016
The 2016 ESC heart failure guidelines strongly recommend Ferinject® for the treatment of iron deficiency in patients with systolic heart failure
23.05.2016
Vifor Pharma appoints Colin Bond as Chief Financial Officer
10.05.2016
Vifor Pharma Licenses Rights to Commercialize ChemoCentryx's Orally-Administered Complement 5aR Inhibitor CCX168 for Orphan and Rare Renal Diseases in Europe and Certain Other Major Markets
Vifor Fresenius Medical Care Renal Pharma and OPKO Health Enter into Agreement for OPKO's RAYALDEE®
09.05.2016
Vifor Fresenius Medical Care Renal Pharma and Relypsa announce Submission of Marketing Authorisation Application Requesting European Approval of Patiromer for treatment of hyperkalemia
25.04.2016
Soho Flordis International signs an agreement for the acquisition of Potters and the Equazen(TM) brand portfolio from Vifor Pharma
22.10.2015
Meta-analysis links Ferinject® treatment of iron deficiency to reduced rate for cardiovascular hospitalisations and deaths in systolic heart failure patients
31.08.2015
Vifor Fresenius Medical Care Renal Pharma and Relypsa enter into partnership to commercialize Patiromer FOS in Europe and additional territories
11.08.2015
Vifor Fresenius Medical Care Renal Pharma: Expansion of product portfolio and establishment of a marketing and sales organisation in Europe
28.05.2015
Velphoro® receives Swissmedic approval for the treatment of hyperphosphatemia in adult patients with chronic kidney disease on dialysis
27.01.2015
Vifor Pharma appoints heads of International Business Operations and Global Marketing
16.09.2014
CONFIRM-HF study demonstrates that Ferinject® improves exercise capacity in patients with chronic heart failure
01.09.2014
Velphoro® receives EU marketing authorisation for treatment of hyperphosphatemia in adult CKD patients on dialysis
27.08.2014
Velphoro® recommended for approval in the European Union for the treatment of hyperphosphatemia in adult Chronic Kidney Disease patients on dialysis
27.06.2014
New Website highlights the serious impact of Iron Deficiency
27.03.2014
Velphoro® (PA21) receives US FDA approval
28.11.2013
Ferinject® reduces or delays requirement for alternative anaemia management compared with oral iron therapy
11.11.2013
Vifor Pharma and Zeria Pharmaceutical Co., Ltd. enter into an exclusive licensing agreement for Ferinject® in Japan
13.08.2013
Injectafer® receives US FDA approval for the treatment of Iron Deficiency Anaemia
26.07.2013
FIND-CKD study demonstrates that Ferinject® reduces need for alternative anaemia treatment
10.07.2013
PDUFA action date for PA21 New Drug Application set by US FDA
15.04.2013
New PDUFA action date announced by the US FDA for Injectafer® New Drug Application
08.04.2013
PA21 authorisation application submitted in Switzerland
12.03.2013
PA21 dossier submitted for approval to US FDA
11.02.2013
Observational study suggests a role for Ferinject® (ferric carboxymaltose) in optimizing the care of anaemic and iron deficient patients with cancer
31.01.2013
Vifor Pharma and China Medical System Holdings Limited sign distribution agreement for Maltofer® and Uro-Vaxom® in China
17.01.2013
PA21 Pivotal phase III data presented at American Society of Nephrology (ASN) Kidney Week demonstrate successful control of hyperphosphatemia with lower pill burden for patients
05.11.2012
Venofer® (Iron Sucrose Injection, USP) receives US FDA approval for Paediatric Indication
26.09.2012
New Guidelines Issued by a Number of Global Medical Committees Prioritise Management of Iron Deficiency to Improve Patient Outcomes
17.09.2012
PA21: Pivotal phase III study met primary and secondary endpoints - Preparations for regulatory filings are under way
09.07.2012
A single 1,000 mg dose of Ferinject® rapidly improves fatigue symptoms in iron deficient, non-anaemic women
17.04.2012
Galenica strengthens its market position in Spain. It acquires all shares of Vifor Uriach Pharma as well as Grupo Uriach's Primary Care Business.
15.11.2011
New Injectafer® (US brand name of Ferinject®) data presented at the American Society of Nephrology's Kidney Week 2011
14.11.2011
Injectafer® NDA submitted to the US Food and Drug Administration
13.10.2011
Vifor Fresenius Medical Care Renal Pharma Ltd. receives approval from European and Swiss antitrust authorities
06.10.2011
Vifor Pharma and Hikma Pharmaceuticals to collaborate in Middle East and North Africa
17.08.2011
MORE NEWS
Financial Calendar
08
August
Half Year Results 2018
MORE DATES
WORKING AT VIFOR PHARMA
Together we are making a difference: Finding new solutions, delivering high-quality products, driving scientific excellence and helping people around the world.
Read more
BUSINESS DEVELOPMENT
REPORTS
Download Annual Report 2017
SHARE PRICE
Detailed information